NCT01646151

A Study Comparing IOP-Lowering Treatments to Bimatoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 2,580 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

An observational study comparing changing from an IOP-lowering treatment to a bimatoprost-containing IOP treatment in primary open-angle glaucoma (POAG) or ocular hypertension (OHT). Visits and treatment are per normal clinical practice.

Conditions

• Glaucoma, Open-Angle
• Ocular Hypertension

Interventions

Type	Name	Description
DRUG	Bimatoprost	Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.

Timeline

• Start date: 2012-05-01
• Primary completion: 2013-04-01
• Completion: 2013-04-01
• First posted: 2012-07-20
• Last updated: 2014-06-13
• Results posted: 2014-06-13

Locations

2 sites across 2 countries: Germany, Netherlands